- Previous Close
1.1000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 1.2500 - Volume
0 - Avg. Volume
16,169 - Market Cap (intraday)
91.333M - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date May 30, 2025 - Jun 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
www.geminalabs.comRecent News: GLAB.CN
View MorePerformance Overview: GLAB.CN
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLAB.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLAB.CN
View MoreValuation Measures
Market Cap
91.33M
Enterprise Value
92.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-138.31%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.41M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
41.61k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
82.35k